The Impact of Isoniazid Resistance on the Treatment Outcomes of Smear Positive Re-Treatment Tuberculosis Patients in the State of Andhra Pradesh, India

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Deepa, Dorai ^a   Achanta, Shanta ^b   Jaju, Jyoti ^b   Rao, Koteswara ^a   Samyukta, Rani ^c   Claassens, Mareli ^d   Kumar, Ajay M V ^e   PH, Vishnu ^a  

^a Government of Andhra Pradesh   (India)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c GOVERNMENT OF INDIA   (India)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE REGISTRY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PATIENT TRANSPORT; RELAPSE; RETREATMENT; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPUTUM SMEAR; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; DEMOGRAPHY; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INDIA; ISONIAZID; MALE; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84885414180     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076189     Document Type: Article

References (14)

1. World Health Organization (2008) The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report No. 4 World Health Organization Document WHO/HTM/TB/2008.394: 1-120.
2. World Health Organization (2010) Treatment of tuberculosis: guidelines for national programmes. fourth edition. World Health Organization Document WHO/HTM/TB/2009.420: 1-147.
3. Central TB, Division (2011) Managing the RNTCP in your area- A training course (Modules 1-4) and (Modules 1-9). Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Available: http://www.tbcindia.nic.in/documents.asp#. Accessed 2013 June 12.
4. World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. World Health Organization Document WHO/HTM/TB/2008.402: 1-247.
5. Vijay S, Balasangameshwara VH, Jagannatha PS, Saroja VN, Shivashankar D, et al. (2002) Re-treatment outcome of smear positive tuberculosis cases under DOTS in Bangalore City. Indian J Tuberc 49: 195-204.
6. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J (2012) Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 16: 812-816. PubMed: 22507372.
7. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, et al. (2011) Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape province, South Africa. Clin Infect Dis 53: 369-372. doi:10.1093/cid/cir406. PubMed: 21810750.
8. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 283: 2537-2545. doi:10.1001/jama.283.19.2537. PubMed: 10815117.
9. Menzies D, Benedetti A, Paydar A, Royce S, Pai M, et al. (2009) Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLOS Med 6(9):: e1000150. doi:10.1371/journal.pmed.1000150. PubMed: 20101802.
10. Central TB, Division (2012) Revised National Tuberculosis Control Programme Guidelines on Progammatic Management of Drug Resistant TB. Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Available: http://tbcindia.nic.in/pdfs/Guidelines%20for%20PMDT%20in%20India%20-%20May%202012.pdf. Accessed 2013 June 12.
11. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, et al. (2010) Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis. A randomized clinical trial. Am J Respir Crit Care Med 181: 743-751. doi:10.1164/rccm.200903-0439OC. PubMed: 19965813.
12. Jha UM, Satyanarayana S, Dewan PK, Chadha S, Wares F, et al. (2010) Risk factors for treatment default among re-treatment tuberculosis patients in India, 2006. PLOS ONE 5(1):: e8873. doi:10.1371/journal.pone.0008873. PubMed: 20111727.
13. Central TB, Division (2011) TB India 2011. Revised National TB Control Programme Annual Status Report; Directorate General of Health Services Ministry of Health and Family Welfare,Government of India Available:http://www.tbcindia.nic.in/pdfs/RNTCP%20TB%20India%202011.pdf. Accessed 2013 June 12.
14. Chadha SS, Sharath BN, Reddy K, Jaju J, Vishnu PH, et al. (2011) Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLOS ONE 6(11):: e26659. doi:10.1371/journal.pone.0026659. PubMed: 22073182.